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Background: Monitoring inﬂuenza virus susceptibility to neuraminidase (NA) inhibitors (NAIs) is vital for
detecting drug-resistant variants, and is primarily assessed using NA inhibition (NI) assays, supplemented by NA sequence analysis. However, differences in NI testing methodologies between surveillance
laboratories results in variability of 50% inhibitory concentration (IC50) values, which impacts data
sharing, reporting and interpretation. In 2011, the Centers for Disease Control and Prevention (CDC), in
collaboration with the Association for Public Health Laboratories (APHL) spearheaded efforts to standardize ﬂuorescence-based NI assay testing in the United States (U.S.), with the goal of achieving consistency of IC50 data.
Methods: For the standardization process, three participating state public health laboratories (PHLs),
designated as National Surveillance Reference Centers for Inﬂuenza (NSRC-Is), assessed the NAI susceptibility of the 2011e12 CDC reference virus panel using stepwise procedures, with support from the
CDC reference laboratory. Next, the NSRC-Is assessed the NAI susceptibility of season 2011e12 U.S.
inﬂuenza surveillance isolates (n ¼ 940), with a large subset (n ¼ 742) tested in parallel by CDC. Subsequently, U.S. inﬂuenza surveillance isolates (n ¼ 9629) circulating during the next three inﬂuenza
seasons (2012e15), were independently tested by the three NSRC-Is (n ¼ 7331) and CDC (n ¼ 2298).
Results: The NI assay IC50s generated by respective NSRC-Is using viruses and drugs prepared by CDC
were similar to those obtained with viruses and drugs prepared in-house, and were uniform between
laboratories. IC50s for U.S. surveillance isolates tested during four consecutive inﬂuenza seasons (2011
e15) were consistent from season to season, within and between laboratories.
Conclusion: These results show that the NI assay is robust enough to be standardized, marking the ﬁrst
time IC50 data have been normalized across multiple laboratories, and used for U.S. national NAI susceptibility surveillance.
Published by Elsevier B.V.
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1. Introduction
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2
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0166-3542/Published by Elsevier B.V.

Neuraminidase (NA) inhibitors (NAIs) are currently the only
class of antiviral drugs recommended by Centers for Disease Control and Prevention (CDC) for the control of inﬂuenza infections,
due to widespread resistance to the M2 blockers (adamantanes)
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(Deyde et al., 2007). In 1999, orally administered oseltamivir and
inhaled zanamivir were approved by the United States (U.S.) Food
and Drug Administration (FDA) for control of inﬂuenza type A and B
infections. In December 2014, a third NAI, intravenous peramivir
(Shetty and Peek, 2012), was FDA-approved. Peramivir is also
licensed in Japan, South Korea and China, while inhaled laninamivir
(Yamashita et al., 2009) is approved in Japan. Intravenous zanamivir
has been provided for compassionate use in recent years, and is
undergoing evaluation for treatment of hospitalized patients with
severe inﬂuenza (https://clinicaltrials.gov/show/NCT01231620).
During initial post-marketing years, monitoring inﬂuenza virus
susceptibility to NAIs was carried out by a central laboratory contracted by the Neuraminidase Inhibitor Susceptibility Network
(NISN) which utilized chemiluminescence- and ﬂuorescence-based
NI assays (Wetherall et al., 2003). Later, monitoring NAIsusceptibility became an integral part of virological surveillance
within the WHO Global Inﬂuenza Surveillance and Response System (WHO-GISRS), where both functional (NA inhibition) and
sequence-based (pyrosequencing, real time RT-PCR, Sanger) assays
have been utilized to conduct drug susceptibility monitoring
worldwide (Monto et al., 2006; Meijer et al., 2014). Following the
FDA's approval of zanamivir and oseltamivir, CDC implemented the
NI assay, ﬁrst using a chemiluminescence-based (Mungall et al.,
2004), then a ﬂuorescence-based methodology (OkomoAdhiambo et al., 2013). The NI assay testing is done for the purpose of monitoring changes in the baseline NAI susceptibility of
circulating inﬂuenza viruses.
Historically, there has been signiﬁcant variability in IC50 data
(the drug concentration required to inhibit 50% of viral NA enzyme
activity), due to factors such as variations in assay choice and/or
assay conditions. The lack of standardization in NI assay methodologies and the resulting IC50 variability has been a challenge in
sharing and interpreting IC50 data among laboratories. In 2012, in
efforts to harmonize the interpretation and reporting of IC50 data,
the WHO Expert Working Group for GISRS on Surveillance of
Antiviral Susceptibility (WHO-AVWG) agreed on criteria to deﬁne
inﬂuenza viruses as exhibiting normal, reduced (RI) or highly
reduced (HRI) NA inhibition, based on the fold change of their IC50
compared to reference IC50 values (WHO, 2012). These criteria have
been helpful in interpretation and reporting of NI assay data
generated by different WHO Collaborating Centers (OkomoAdhiambo et al., 2014; Takashita et al., 2014, 2015a), and for
providing annual global updates (Meijer et al., 2014; Takashita et al.,
2015b). Viruses of N1 subtype carrying the H275Y substitution in
the NA (H274Y in N2 subtype) and A(H3N2) viruses carrying E119V
or R292K substitutions consistently demonstrate HRI by oseltamivir in NI assays (Meijer et al., 2014; Okomo-Adhiambo et al., 2014;
Takashita et al., 2015b).
In the summer of 2011, the CDC spearheaded efforts to standardize inﬂuenza NI testing within the U.S., in collaboration with
the Association for Public Health Laboratories (APHL) and several
state public health laboratories (PHLs), with the goal of minimizing
NI assay IC50 data variability within and among surveillance laboratories, as well as increasing the US capacity to monitor the NAI
susceptibility of inﬂuenza viruses. Three PHLs, designated as National Surveillance Reference Centers for Inﬂuenza (NSRC-Is),
namely, the California Department of Public Health (CDPH), Richmond, CA; Uniﬁed State Laboratories, Public Health (USLPH), Taylorsville, UT; and the Wisconsin State Laboratory of Hygiene
(WSLH), Madison, WI, participated in the “Project for Standardization of NAI Susceptibility Testing,” through a step-wise procedure
developed by the CDC. In April 2012, Maryland Department of
Health and Mental Hygiene (MD DHMH) Laboratories Administration also participated in an additional NI Standardization Project,
but was not selected as a NSRC-I.
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After successfully completing the standardization process, the
three NSRC-Is performed NI assay testing on U.S. inﬂuenza surveillance specimens collected during the 2011e12 season, and
three subsequent seasons, 2012e13, 2013e14, and 2014e15. The NI
assay testing activity was added to an ongoing APHL contract for
inﬂuenza virus isolation, collectively referred to as the “VI/NI
Project.” At CDC, standardized IC50 data generated by the NSRC-Is
were further analyzed based on criteria of the WHO-AVWG
(WHO, 2012) to identify viruses with RI or HRI, which were
genetically analyzed by pyrosequencing and/or conventional NA
sequence analysis to determine underlying NA changes responsible
for elevated IC50s. Viruses with markers previously associated with
resistance to NAI(s) were reported as NAI-resistant to the WHO
GISRS and in the U.S. inﬂuenza virological surveillance Report
(FluView) (http://www.cdc.gov/ﬂu/weekly/).
This report describes results of the NI assay standardization
project performed on the 2011e12 CDC reference virus panel by
three NSRC-Is (CDPH, USLPH and WSLH), as well as NI assay data for
U.S. inﬂuenza surveillance isolates they tested during seasons
2011e15. These results suggest that NAI drug susceptibility data
generated in the NI assay can be interpreted and shared in a
consistent, reproducible manner when detailed procedures and
reference materials are used in assay implementation.
2. Materials and methods
2.1. Training
Prior to the standardization process, participating laboratories
received training on the ﬂuorescent NI assay by CDC laboratorians,
through lectures and hands-on instruction. The training course,
conducted in April 2011, was sponsored by the APHL, CDC and
National Laboratory Training Network (NLTN), and comprised preand post-test knowledge assessment; background information on
inﬂuenza and drug susceptibility testing; NI assay workﬂow; reagent and drug preparation; determination of virus dilutions for
use in the NI assay; identiﬁcation of acceptable NI assay results;
equipment operation; IC50 data analysis and interpretation.
2.2. Viruses
The 2011e12 CDC reference panel (Table 1) comprising wildtype
and variant virus pairs of seasonal inﬂuenza types/subtypes, as well
as surveillance isolates circulating during the 2011e14 inﬂuenza
seasons were propagated in MadineDarby canine kidney (MDCK)
cells provided by CDC. Since October, 2014 (season 2014e15)
inﬂuenza A(H3N2) viruses are propagated in MDCK-SIAT1 cells,
also provided by CDC. Note, an updated CDC reference virus panel
version 2, for NAI susceptibility testing, was introduced in October,
2012 (season 2012e13), and comprises viruses different from those
in the 2011e2012 panel, with exception of A/Washington/01/
2007(H3N2) wildtype, A/Texas/12/2007(H3N2) NA-E119V, B/
Memphis/20/96 wildtype and B/Memphis/20/96 NA-R152K
(Supplementary Table S1). Laboratories conducting inﬂuenza
virological surveillance using NI assays can obtain this panel from
the Inﬂuenza Reagent Resource (IRR) upon registration and
approval
(Catalogue
No.
FR-1176)
(http://
www.inﬂuenzareagentresource.org/Catalog.aspx).
2.3. Neuraminidase inhibitors
Oseltamivir carboxylate, the active compound of the ethyl ester
prodrug oseltamivir phosphate was kindly provided by HoffmannLa Roche (Basel, Switzerland), zanamivir by GlaxoSmithKline
(Uxbridge, UK), and peramivir by BioCryst Pharmaceuticals
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Table 1
Fluorescent NI assay IC50s for the 2011e12 CDC reference virus panel, tested by CDC.
Virus name

A/California/07/2009 Wildtype
A/North Carolina/39/2009 H275Y
A/Washington/10/2008 Wildtype
A/Florida/21/2008 H275Y
A/Washington/01/2007 Wildtype
A/Texas/12/2007 E119V
B/Memphis/20/1996 Wildtype
B/Memphis/20/1996 R152K

Inﬂuenza type/subtype

A(H1N1)pdm09
A(H1N1)pdm09
A(H1N1)
A(H1N1)
A(H3N2)
A(H3N2)
B
B

Mean IC50 ± SDa [Range]b (nM)
Oseltamivir

Zanamivir

Peramivir

0.21 ± 0.02 [0.19e0.23]
151.13 ± 12.08 [140.04e164.00]
0.59 ± 0.08 [0.50e0.65]
562.97 ± 55.49 [504.00e614.15]
0.06 ± 0.01 [0.05e0.07]
45.36 ± 7.30 [40.42e53.75]
4.45 ± 0.19 [4.28e4.65]
600.38 ± 84.81 [523.81e690.89]

0.20 ± 0.01 [0.19e0.21]
0.22 ± 0.01 [0.21e0.22]
0.25 ± 0.05 [0.21e0.30]
0.52 ± 0.08 [0.43e0.58]
0.69 ± 0.14 [0.55e0.82]
0.46 ± 0.05 [0.43e0.51]
1.19 ± 0.04 [1.16e1.24]
62.60 ± 5.18 [56.87e66.96]

0.05 ± 0.05 [0.05e0.05]
17.75 ± 0.66 [17.03e18.33]
0.07 ± 0.01 [0.06e0.08]
73.48 ± 10.61 [61.63e82.11]
0.08 ± 0.01 [0.07e0.09]
0.10 ± 0.09 [0.09e0.11]
0.30 ± 0.02 [0.29e0.32]
278.22 ± 21.16 [254.17e293.99]

Abbreviations - SD: Standard deviation.
a
Three independent NI assays.
b
Range: minimum to maximum IC50.

(Birmingham, AL). Note, oseltamivir, zanamivir and peramivir are
also available commercially (Sequoia Research Products, Pangbourne, United Kingdom). In this study, NAIs (in powder form)
were obtained from respective manufacturers through material
transfer agreements (MTAs), then weighed and reconstituted using
deionized distilled water (to 20 mM solutions), according to procedures described in the CDC ﬂuorescent NI assay protocol. These
20 mM solutions were then diluted into 50 mM stock solutions,
which were used to prepare 3.16-fold (half-log10) serial dilutions of
NAIs (total of 10), starting from 4 mM (4000 nM) to a ﬁnal concentration of 0.12 nM.

detailed standard operating procedure (SOP) for the ﬂuorescent NI
assay utilizing the NA-Fluor™ Inﬂuenza Neuraminidase Assay Kit
(Okomo-Adhiambo et al., 2013). Besides the SOP, the CDC also
provided materials and tools, including a virus dilution calculator
tool; JASPR v1.2 curve-ﬁtting software (CDC, Atlanta, GA); the
2011e12 CDC reference virus panel; aliquots of veriﬁed 50 mM NAI
stock solutions (for the ﬁrst phase of the study); and technical
support for troubleshooting. Additionally, CDC laboratorians conducted site visits to monitor NI assay implementation for the
impending 2011e12 inﬂuenza season.
2.6. Testing algorithm for NI assay standardization

2.4. Neuraminidase inhibition assay
Virus susceptibility to NAIs was assessed in the ﬂuorescent NI
assay that utilizes 2-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid (MUNANA) as substrate. The assay was performed using the NA-Fluor™ Inﬂuenza Neuraminidase Assay Kit (Applied
Biosystems/Life Technologies, Carlsbad, CA) in 96-well opaque
black ﬂat-bottom microplates (Corning Inc., Corning, NY), according to the CDC protocol, which can be requested by email
(ﬂuantiviral@cdc.gov). The CDC ﬂuorescent NI assay protocol is
optimized to the needs of virological surveillance (OkomoAdhiambo et al., 2013) and somewhat differs from the manufacturer's instructions in the NA-Fluor™ kit manual. Brieﬂy, viruses
were diluted at concentrations corresponding to the target ﬂuorescence signal generated by 1000 pmol/well of 4methylumbelliferone (4-MU) standard. A virus dilution calculation spreadsheet (Excel, Microsoft, Redmond, WA) was used to
determine the appropriate dilution of virus to be used in the inhibition portion of the assay. This tool rapidly provides the dilutions
of virus, together with the volumes of virus and 1 NA-Fluor™
Assay Buffer to be used. Subsequently, 25 mL of each diluted virus
was mixed with 25 mL of a range of concentrations of each NAI
(0.12 nMe4000 nM; with a ﬁnal concentration in the reaction of
0.03 nMe1000 nM) and incubated at 37  C for 45 min, after which
50 mL of the 200 mM NA-Fluor™ Substrate (MUNANA) was added to
the virus and inhibitor mix, and incubated at 37  C for 60 min. The
reaction was terminated with 100 mL NA-Fluor™ Stop Solution.
Fluorescence was detected on the Victor3 V™ (USLPH), Victor X4™
(WSLH) or Victor X2™ (CDPH) plate reader (PerkinElmer, Shelton,
CT), equipped with ﬁlters for excitation (l ¼ 365 nm) and emission
(l ¼ 450 nm). Note, the CDC currently uses the BioTek™ plate
reader platform, models Synergy H1™, Synergy Neo™ and Cytation
3™ (BioTek Instruments Inc., Winooski, VT).
2.5. Resources provided by CDC
Participating laboratories (NSRC-Is) were provided with a

In the ﬁrst phase of the standardization process, participating
laboratories (NSRC-Is) performed the NI assay on 2011e12 CDC
reference panel viruses grown by CDC (n ¼ 8), using NAIs that the
CDC obtained, weighed, reconstituted and diluted. The laboratories
were provided with 50 mM NAI stock solutions which they diluted
to the ﬁnal concentrations (0.12e4000 nM) required for NI assay
testing. For the second phase, participating laboratories prepared
their own stocks of the 2011e12 CDC reference panel viruses, and
tested them with NAIs they obtained from manufacturers in powder form, and weighed, reconstituted and diluted in-house.
Commonly, each NI assay test was replicated at least twice. After
successfully completing the NI assay standardization process, the
NSRC-Is tested U.S. inﬂuenza A and B surveillance isolates collected
during the 2011e12 season (n ¼ 940), using NAIs obtained and
prepared in-house. A subset (n ¼ 742) of these viruses were tested
in parallel by the CDC. The 2011e12 CDC reference panel inﬂuenza
A(H1N1)pdm09 viruses, A/California/07/2009 wildtype and A/
North Carolina/39/2009 H257Y, were included in each NI assay test
as controls. Note, the tested surveillance isolates were propagated
by NSRC-Is as part of the VI/NI project or by CDC (viruses submitted
to CDC directly), and NAIs were prepared by each NSRC-I and the
CDC, respectively. Subsequently, the NSRC-Is tested surveillance
isolates (n ¼ 6773) circulating during the 2012e15 inﬂuenza seasons; the A(H1N1)pdm09 viruses, A/California/12/2012 wildtype
and A/Texas/23/2012 H275Y, from CDC reference virus panel
version 2, were included in each NI assay test for quality control. All
NI assay data generated by the NSRC-Is were submitted to the CDC
for evaluation via secure ﬁle transfer protocol (FTP).
2.7. Data analysis
Fifty percent inhibitory concentration (IC50) values were determined using JASPR v1.2 curve-ﬁtting software (CDC, Atlanta, GA) by
participating laboratories. The CDC laboratory performed statistical
analyses of IC50 values using SAS v9.3 (SAS Institute, Cary, NC), with
statistical signiﬁcance set at a ¼ 0.05. One-way analysis of variance
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prepared NAIs (Table 2) were similar and exhibited minimal
inter-assay variation within respective laboratories. There was
minimal inter-laboratory variation in IC50s, which, with few exceptions, was statistically insigniﬁcant. For example, the zanamivir
IC50 for A/Washington/10/2008(H1N1) wildtype virus generated by
WSLH (0.32 nM) was 2-fold greater than that for CDPH (0.16 nM),
while zanamivir IC50 for B/Memphis/20/1996 R152K variant virus
generated by CDPH (67.94 nM) was 2-fold more than for USLPH
(33.13 nM) and WSLH (43.20 nM). Similarly, the peramivir IC50 for
A/Washington/01/2007(H3N2) wildtype virus generated by WSLH
(0.14 nM) was 2-3-fold higher compared to those of CDPH
(0.06 nM) and USLPH (0.05 nM). These differences were not statistically signiﬁcant (p > 0.05).
Using viruses they propagated and NAIs prepared in-house, the
participating laboratories were able to successfully reproduce the
IC50s they generated using the viruses and NAIs prepared by the
CDC (p-values comparing IC50s derived from the two scenarios
were insigniﬁcant, range 0.073e0.980). These IC50s also exhibited
minimal inter-assay and inter-laboratory variation, although those
generated by USLPH tended to be lower (2-fold) compared to
those of CDPH and WSLH. However, these differences were
generally <2-fold and were not signiﬁcant at the assessed level of
conﬁdence (p > 0.05). Overall, the IC50s for the 2011e12 reference
virus panel generated by the three laboratories for the standardization process, were comparable to those generated by the CDC for
the same reference virus panel (Table 1), and were within the
ranges expected for wildtype and NA variant virus pairs of the four
inﬂuenza type/subtypes that were assessed.
Upon completion of testing the 2011e12 CDC reference virus
panel for the standardization process, and implementing the NI

(ANOVA) was used to compare means of IC50s generated for the
2011e12 reference virus panel tested for the standardization process, while non-parametric ANOVA (Pappas and DePuy, 2004) was
used to compare medians of IC50s for the 2011e15 U.S. surveillance
isolates.
2.8. Sequence analysis
To identify known and/or novel markers associated with
elevated IC50, viral RNA was extracted from isolates and NA
sequence analyzed by pyrosequencing (Deyde and Gubareva, 2009)
and/or Sanger sequencing (Sheu et al., 2008). Amino acid substitutions are named according to speciﬁc inﬂuenza A NA subtype
or B type sequence numbering (straight numbering).
3. Results
The NI assay standardization process was conducted on the
2011e12 CDC reference virus panel (Table 1) comprising four pairs
of wildtype virus and NA variants with known molecular markers
previously associated with elevated IC50s for one or more NAIs,
covering a wide range of IC50 values. The three participating laboratories designated as NSRC-Is (CDPH, USLPH, and WSLH), ﬁrst
tested the 2011e12 CDC reference virus panel propagated by CDC,
using NAIs obtained and prepared by the CDC (the laboratories
were provided with 50 mM stock solutions which they diluted
further). This was followed by testing of the same reference virus
panel propagated by each participating laboratory, and using NAIs
they obtained and prepared in-house (Table 2).
The IC50s generated for CDC-propagated viruses with CDC-

Table 2
Fluorescent NI assay IC50s for the 2011e12 CDC reference virus panel, tested by three NSRC-Is (CDPH, USLPH and WSLH) for the standardization process.
NAI

Virus name

Inﬂuenza type/Subtype Mean IC50 ± SD (nM)
CDC Drug/Virusa,y
CDPH

Oseltamivir A/California/07/2009 Wildtype
A/North Carolina/39/2009 H275Y
A/Washington/10/2008 Wildtype
A/Florida/21/2008 H275Y
A/Washington/01/2007 Wildtype
A/Texas/12/2007 E119V
B/Memphis/20/1996 Wildtype
B/Memphis/20/1996 R152K
Zanamivir
A/California/07/2009 Wildtype
A/North Carolina/39/2009 H275Y
A/Washington/10/2008 Wildtype
A/Florida/21/2008 H275Y
A/Washington/01/2007 Wildtype
A/Texas/12/2007 E119V
B/Memphis/20/1996 Wildtype
B/Memphis/20/1996 R152K
Peramivir
A/California/07/2009 Wildtype
A/North Carolina/39/2009 H275Y
A/Washington/10/2008 Wildtype
A/Florida/21/2008 H275Y
A/Washington/01/2007 Wildtype
A/Texas/12/2007 E119V
B/Memphis/20/1996 Wildtype
B/Memphis/20/1996 R152K

A(H1N1)pdm09
A(H1N1)pdm09
A(H1N1)
A(H1N1)
A(H3N2)
A(H3N2)
B
B
A(H1N1)pdm09
A(H1N1)pdm09
A(H1N1)
A(H1N1)
A(H3N2)
A(H3N2)
B
B
A(H1N1)pdm09
A(H1N1)pdm09
A(H1N1)
A(H1N1)
A(H3N2)
A(H3N2)
B
B

0.15
140.44
0.38
431.27
0.05
34.21
3.88
472.84
0.15
0.14
0.16
0.52
0.76
0.26
0.71
67.94
0.04
14.97
0.04
65.60
0.06
0.08
0.23
256.27

PHL Drug/Virusb,y

USLPH
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

0.06
15.58
0.08
44.64
0.01
0.62
1.03
47.23
0.02
0.01
0.01
0.09
0.35
0.08
0.21
2.20
0.01
0.40
0.01
0.00
0.01
0.02
0.09
32.63

0.16
120.58
0.42
319.71
0.04
33.53
3.11
421.62
0.16
0.17
0.23
0.61
0.75
0.35
0.81
33.13
0.04
15.63
0.05
67.89
0.05
0.08
0.24
215.92

WSLH
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

0.11
36.71
0.27
124.5
0.01
12.75
1.93
120.11
0.05
0.06
0.09
0.37
0.48
0.12
0.35
24.59
0.01
3.94
0.02
11.48
0.02
0.02
0.06
35.38

0.11
135.39
0.34
404.18
0.04
28.48
2.72
410.49
0.14
0.16
0.32
0.76
0.60
0.34
0.74
43.20
0.03
13.98
0.04
64.32
0.14
0.06
0.20
208.57

±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

0.02
15.85
0.06
19.11
0.01
5.23
0.56
48.62
0.03
0.03
0.12
0.21
0.26
0.07
0.09
12.21
0.01
2.66
0.01
11.59
0.10
0.02
0.04
52.42

CDPHc

USLPH

0.09
128.76
0.36
399.73
0.04
33.01
2.46
469.35
0.13
0.12
0.17
0.45
0.52
0.25
0.59
49.90
0.04
18.97
0.05
71.17
0.06
0.09
0.26
245.65

0.12
117.02
0.33
234.54
0.04
27.45
2.40
311.30
0.16
0.20
0.23
0.54
0.93
0.38
0.76
23.73
0.05
17.45
0.07
68.14
0.07
0.10
0.35
229.11

WSLH
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

0.03
21.62
0.08
33.06
0.00
6.26
0.51
37.50
0.03
0.01
0.01
0.06
0.47
0.01
0.09
4.45
0.01
1.89
0.02
6.59
0.02
0.03
0.13
43.03

0.18 ± 0.06
146.64 ± 16.7
0.96 ± 0.97
452.63 ± 79.77
0.04 ± 0.01
39.76 ± 17.68
3.30 ± 1.79
473.88 ± 37.41
ed
e
e
e
e
e
e
e
0.02 ± 0.01
14.45 ± 1.4
0.06 ± 0.03
67.61 ± 14.61
0.05 ± 0.01
0.06 ± 0.02
0.18 ± 0.02
244.9 ± 78.28

Abbreviations e PHL: state public health laboratory; CDPH: California Department of Public Health; USLPH: Utah Uniﬁed State Laboratories-Public Health; WSLH: Wisconsin
State Laboratory of Hygiene. SD: standard deviation.
y
ANOVA p-values (a ¼ 0.05) comparing IC50 means generated using CDC virus/drug vs PHL virus/drug, for each respective PHL and virus, were all insigniﬁcant (range of pvalues 0.073e0.980).
a
CDC-propagated virus tested with CDC-reconstituted drug (PHLs diluted provided 50 mM solutions). Assay replicated twice.
b
PHL-propagated virus tested with PHL-reconstituted/diluted drug. Assay replicated twice, with exceptions.
c
Assay performed only once.
d
Zanamivir not available for testing.
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assay, the three NSRC-Is (CDPH, USLPH and WSLH) performed the
NI assay on 2011e12 U.S. inﬂuenza surveillance specimens
(Table 3), in efforts to strengthen domestic inﬂuenza virological
surveillance. A total of 940 virus isolates were tested by the NSRCIs, of which 742 (80%) were tested in parallel by CDC for data quality
purposes, and to enable testing of virus susceptibility to investigational laninamivir (data not shown). Within individual laboratories, there was minimal inter-assay variation in IC50s for the
respective NAIs and virus type/subtypes (Table 3). Inter-laboratory
variation in IC50s was also minimal, with few exceptions that were
not statistically signiﬁcant (p > 0.05). For example, the mean
oseltamivir IC50 for A(H1N1)pdm09 viruses generated by WSLH
(0.12 nM) was ~2-fold lower than that for CDPH (0.19 nM) and only
slightly less than for USLPH (0.16 nM). Similarly, the mean peramivir IC50 for B viruses generated by WSLH (0.27 nM) was ~2-fold
lower than those for CDPH (0.49 nM) and USLPH (0.54 nM). Overall,
the IC50s for respective NAIs and virus type/subtypes generated by
the NSRC-Is, were consistent and comparable with those generated
by the CDC for the same set of viruses (Table 3).
As outlined in the CDC SOP for the ﬂuorescent NI assay, the pair
of A(H1N1)pdm09 viruses, A/California/07/2009 wildtype and A/
North Carolina/39/2009 NA-H275Y, from the 2011e12 CDC reference panel, were propagated by NSRC-Is to prepare sizeable stocks
to enable aliquots of these viruses to be included in each NI assay
test for quality control purposes. Note, in October 2012, these viruses were replaced by the A(H1N1)pdm09 virus pair, A/California/
12/2012 wildtype and A/Texas/23/2012 H275Y, that are in the
current CDC reference virus panel version 2.
Following successful NI assay testing in season 2011e12, the
three NSRC-Is continued testing U.S. surveillance isolates
(n ¼ 6773) circulating during the 2012e13 (n ¼ 2114), 2013e14
(n ¼ 2756) and 2014e15 (n ¼ 1903) inﬂuenza seasons. During these
three seasons, as well as the previous 2011e12 season, the NSRC-Is
assessed virus susceptibility to three NAIs, oseltamivir, zanamivir
and peramivir, but in 2012e13 they did not monitor peramivir
susceptibility. Median IC50s for oseltamivir, zanamivir and peramivir generated by the NSRC-Is during four inﬂuenza seasons
(2011e15) were generally uniform within individual laboratories
from season to season (Fig. 1), although a few exceptions were
noted. Within WSLH, the median IC50 for peramivir among inﬂuenza A(H1N1)pdm09 viruses in 2011e12 (0.03 nM) was ~2-fold
lower compared to seasons 2013e14 (0.05 nM) and 2014e15

(0.06 nM). Among the NSRC-Is, median IC50s for respective NAIs
and virus type/subtypes were consistent during 2011e2015, with
few exceptions, such as the 2014e15 median IC50 of oseltamivir
among inﬂuenza B generated by CDPH (10.54 nM), which varied by
almost 2-fold compared to USLPH (4.99 nM) and was slightly
higher than that for WSLH (7.15 nM). Overall, the median IC50s
obtained by the NSRC-Is over four seasons (2011e15), for respective
NAIs and virus type/subtypes, were consistent with those generated by CDC (Supplemental Table S2), and differences if any were
2-fold and not statistically signiﬁcant (p < 0.05).
The standardization process signiﬁcantly increased capabilities
for the NI assay in the U.S., with NSRC-Is accounting for ~80% of all
NI testing performed on U.S. surveillance isolates circulating during
the 2012e13, 2013e14 and 2014e15 inﬂuenza seasons. Standardizing the NI assay is, however, not practical for laboratories involved
in monitoring inﬂuenza antiviral susceptibility globally. To address
this issue, WHO-AVWG developed a set of criteria for reporting NI
assay results based on IC50 fold change difference compared to a
reference such as the median IC50 for the respective NAI and virus
type (WHO, 2012). During seasons 2012e15, these criteria were
applied to identify viruses with fold differences above a respective
median IC50 value for the same NAI and type/subtype; viruses
exhibiting RI or HRI were re-tested in the NI assay by NSRC-Is for
the result conﬁrmation and submitted to CDC for comprehensive
characterization. In some instances, epidemiological investigations
were initiated by the CDC (Okomo-Adhiambo et al., 2015; Garg
et al., 2013).
The introduction of the WHO-AVWG criteria (WHO, 2012)
allowed an expanded scope of the original project. Two state PHLs
that were not part of the primary CDC/APHL standardization project, MD DHMH, and the New York State Department of Health
(NYDOH), also conducted NI testing using the NA-Fluor™ Inﬂuenza
Neuraminidase Assay Kit, according to their in-house protocols. The
generated IC50 values were interpreted in accord with the WHOAVWG classiﬁcation criteria. During the 2014e15 season, the MD
DHMH laboratory tested a total of 329 inﬂuenza A(H3N2) (n ¼ 253)
and B (n ¼ 76) viruses collected in the state of Maryland between
Oct 01, 2014 and May 17, 2015. All viruses exhibited normal inhibition by oseltamivir, zanamivir and peramivir, with exception of
one (0.4%) A(H3N2) virus with RI by zanamivir (15-fold increase in
IC50 compared to the median IC50 for the subtype). This virus and its
original clinical specimen were submitted to CDC for further

Table 3
Fluorescent NI assay IC50s for season 2011e12 U.S. inﬂuenza A and B surveillance isolates, tested in parallel by the NSRC-Is and CDC (n ¼ 742).
NAI

Inﬂuenza type/Subtype

Mean IC50 ± SD [Range]a (nM)

Oseltamivir

A(H1N1)pdm09
A(H3N2)
Bh
A(H1N1)pdm09
A(H3N2)
Bh
A(H1N1)pdm09
A(H3N2)
Bh

0.19
0.10
8.04
0.11
0.18
0.79
0.05
0.07
0.49

CDPH (n ¼ 251)

Zanamivir

Peramivir

±
±
±
±
±
±
±
±
±

0.06
0.04
2.42
0.02
0.09
0.29
0.01
0.01
0.21

[0.06e0.38]b
[0.02e0.40]
[0.68e12.77]e
[0.08e0.18]b
[0.09e0.64]
[0.30e1.25]
[0.03e15.47]b
[0.04e0.13]
[0.24e1.48]e

rf

USLPH (n ¼ 248)
0.16
0.11
7.57
0.16
0.24
1.11
0.06
0.09
0.54

±
±
±
±
±
±
±
±
±

0.04
0.02
2.04
0.03
0.05
0.31
0.01
0.02
0.12

[0.10e0.27]c
[0.07e0.20]
[4.91e14.49]
[0.10e0.35] c
[0.13e0.40]
[0.67e1.70]
[0.04e0.09]c
[0.06e0.16]
[0.32e0.90]

WSLH (n ¼ 243)
0.12
0.07
5.45
eg
e
e
0.03
0.06
0.27

± 0.02 [0.07e0.15]d
± 0.03 [0.04e0.26]
± 1.97 [0.10e14.00]

± 0.01 [0.02e0.08]d
± 0.02 [0.04e0.25]
± 0.07 [0.07e0.54]

CDC (n ¼ 742)
0.20
0.12
8.09
0.18
0.28
1.29
0.05
0.09
0.42

±
±
±
±
±
±
±
±
±

0.05
0.05
2.92
0.04
0.11
0.59
0.01
0.02
0.15

[0.11e0.49]b,c,d
[0.04e0.53]
[0.11e16.19]e
[0.12e0.37]b,c,d
[0.12e0.98]
[0.49e2.38]e
[0.03e0.11]b,c,d
[0.04e0.35]
[0.08e1.10]e

0.978
0.714
0.836
0.477
0.491
0.572
0.989
0.265
0.786

Abbreviations - CDPH: California Department of Public Health; USLPH: Utah Uniﬁed State Laboratories-Public Health; WSLH: Wisconsin State Laboratory of Hygiene. SD:
standard deviation.
a
Range: minimum to maximum IC50.
b
Excludes A/Texas/24/2012 H275Y variant (Ose ¼ 122.88 nM; Zan ¼ 0.12 nM; Per ¼ 15.47 nM).
c
Excludes A/Illinois/01/2012 H275Y variant (Ose ¼ 132.67 nM; Zan ¼ 0.21 nM; Per ¼ 17.80 nM).
d
Excludes A/Delaware/03/2012 H275Y variant (Ose ¼ 35.71 nM; Per ¼ 3.18 nM).
e
Excludes B/California/03/2012 A200 A/T variant (Ose IC50 ¼ 30.39 nM; Zan IC50 ¼ 2.11 nM; Per IC50 ¼ 2.39).
f
Pearson correlation coefﬁcient between IC50s generated by PHLs and CDC for the same viruses.
g
Zanamivir was not available for testing.
h
There were no signiﬁcant differences in IC50s between type B virus lineages.
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Fig. 1. Median IC50s of oseltamivir, zanamivir and peramivir obtained by the three NSRC-Is (CDPH, USLPH and WSLH) for U.S. inﬂuenza A and B surveillance isolates circulating
during the inﬂuenza seasons of 2011e12 (n ¼ 940), 2012e13 (n ¼ 2114), 2013e14 (n ¼ 2757) and 2014e2015 (n ¼ 2640). Note, peramivir was not assessed by the three NSRC-Is in
season 2012e13.

characterization. Full NA sequence analysis of the virus isolate
detected the cell culture adaptive Q136K substitution, which was
absent in the matching clinical specimen. The NYDOH laboratory
tested a total of 95 inﬂuenza A(H3N2) (n ¼ 78) and B (n ¼ 17) viruses collected in New York state between Jan 16 and May 01, 2015;
all viruses exhibited normal inhibition by oseltamivir and zanamivir (peramivir was not assessed).
Overall, standardized NI assay procedure with three FDAapproved NAIs, conducted by four laboratories (CDC and three
NSRC-Is) (n ¼ 3015), as well as harmonization of reporting from
two additional laboratories (MD DHMH and NYDOH) (n ¼ 424),
resulted in a total of 3439 circulating U.S. inﬂuenza viruses tested
during the 2014e15 season (Oct 01, 2014 to Jun 23, 2015), including
68 A(H1N1)pdm09, 2174 A(H3N2) and 1197 B viruses. Only two
(0.1%) U.S. viruses with molecular markers of NAI resistance were
detected, including one A(H1N1)pdm09 virus with H275Y and one
A(H3N2) virus with E119V NA substitutions.

4. Discussion
Biochemical NI assays have been the cornerstone of NAI susceptibility monitoring programs. They provide a valuable means to
screen virus isolates to identify those with elevated IC50s which can
indicate potential NAI resistance. Coupled with genetic analysis, the
NI assay is especially valuable when information on drug resistance
markers is not available or sparse, such as when a new NAI is
marketed or a novel virus emerges (Sleeman et al., 2013, 2014). The
IC50 values generated in NI assays also provide information for
comparison of inhibitory effects of different NAIs thus aiding in
identiﬁcation of cross-resistant viruses. Variations in IC50 values
determined for the same virus and drug can arise from sources such
as use of different enzyme substrates (ﬂuorescent vs chemiluminescent), buffer systems, time of incubation, and other assay conditions (Nguyen et al., 2010; McKimm-Breschkin et al., 2003;
McKimm-Breschkin and Barrett, 2014; Tisdale, 2000).
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The goal of the standardization process was to achieve consistency of IC50 data across participating laboratories through the
application of uniform NI assay testing procedures (same kit and
assay protocol) with support from the CDC reference laboratory. In
this study, critical factors including the use of a standardized SOP,
commercial NI assay kit, and the CDC reference virus panel, enabled
the generation of reproducible results among laboratories participating in the NI assay standardization process. Although participating laboratories and the CDC reference laboratory utilized
different plate reader models, all were equipped with standard
ﬁlters for excitation (l ¼ 365 nm) and emission (l ¼ 450 nm), set to
measure ﬂuorescence for 0.1 s. All plate readers were calibrated
prior to their initial use by running 4-methylumbelliferone (4-MU)
standards to verify optimal plate reader settings and to determine
ﬂuorescent signal targeted for virus working dilution. Viruses were
diluted at concentrations corresponding to the target ﬂuorescence
signal generated by 1000 pmol/well of 4-methylumbelliferone (4MU) standard. This procedure was repeated whenever major
repair or recalibration was done to a plate reader. There were no
apparent variations in IC50s attributable to differences in plate
reader models.
The commercially available NA-Fluor™ Inﬂuenza Neuraminidase Assay Kit used in this study provides the necessary assay reagents, but it lacks NAIs and plates. It also does not include
reference material such as inﬂuenza viruses exhibiting a range of
IC50 values. Preparation of NAI and virus dilutions may vary by
laboratory, potentially resulting in IC50 variability. CDC provided
the NAI preparations to see if there were any differences in IC50s for
the viruses tested using CDC-prepared drug compared to testing
done with NAIs prepared in-house. Preparation of NAIs from their
original powder form to concentrations required for the NI assay
involves several steps, in which errors may be introduced. In this
study, the Tocris Molarity Calculator (http://www.tocris.com/
molarityCalculator.php) was used to determine appropriate volumes of water for initial reconstitution of drugs from powder form.
Caution was taken during pipetting to ensure accurate volumes of
water were dispensed when diluting NAIs. Laboratories participating in the standardization project were advised to test newly
prepared NAIs in parallel to old drug preparations, to conﬁrm accuracy in reconstitution and dilution, and ensure consistency.
Although beyond the scope of this study, surveillance laboratories
could explore the option of requesting analytically pre-weighed
NAIs upon placing a purchase order to commercial entities that
offer zanamivir, oseltamivir carboxylate, and peramivir.
In this study, there was no evidence of IC50 variability arising
from drug preparation or viruses; differences in IC50s derived using
CDC- versus PHL-prepared drug were minimal (<2-fold) within
individual laboratories and also between the laboratories. Two-fold
differences in IC50s have been observed among personnel in the
same laboratory. The present study also showed no signiﬁcant
variations in IC50s arising from virus propagation. Nevertheless,
participating laboratories were advised by the CDC to limit the
number of virus passages since it could lead to emergence of NA
changes resulting in elevated IC50s (Tamura et al., 2013; Mishin
et al., 2014).
The success of the NI assay standardization project afﬁrmed that
NAI susceptibility data generated in the NI assay could be shared
and interpreted in a consistent, reproducible manner. The success
of this project can be attributed to several factors including good
laboratory practices; the participating laboratories have standard
practices of annual pipette calibration, as well as maintenance and
performance monitoring of equipment, including plate readers and
incubators. The set of tools developed by CDC and shared with the
three NSRC-Is, including the ﬂuorescent NI assay SOP, virus dilution
calculator, software for IC50 calculation, seeds to propagate in-

house reference virus stocks, as well as other support and guidance, were essential for the success of this project. Hands-on
training of personnel new to NI testing is also desirable, as is
maintaining optimized protocols, as well as necessary reagents,
reference viruses and NAI drug stocks. To sustain the quality of
future NI assay testing, prior to each upcoming inﬂuenza season,
laboratories should test reference panels such as CDC or ISIRV-AVG
(http://www.isirv.org/site/index.php/reference-panel). Ideally, elements of the NI assay including laboratory infrastructure, protocols,
technology, and reagents should be standardized in laboratories in
the U.S. and across the globe. However, many laboratories, especially those in resource-poor countries, lack the infrastructure and
means necessary to develop, validate, and comply with requirements for NI assay standardization.
The successful implementation of NI testing on season 2011e12
surveillance isolates, and subsequent testing of viruses collected
during seasons 2012e15 by the NSRC-Is, proved the effectiveness of
the NI assay standardization and expansion efforts which spanned
5 years, and was instrumental in increasing U.S. domestic inﬂuenza
antiviral surveillance capabilities and pandemic preparedness. This
project marks the ﬁrst time that IC50 data have been standardized
across multiple laboratories performing inﬂuenza antiviral susceptibility testing, and incorporated into the U.S. national virological surveillance. The successful NI assay standardization process
will enable the expansion of the number of surveillance laboratories capable of drug susceptibility testing both nationally and
internationally, assessment of virus susceptibility to new NAIs and
testing of novel viruses. These efforts are expected to signiﬁcantly
impact monitoring of inﬂuenza antiviral resistance, and will ensure
accurate, timely information for public health surveillance.
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SUPPLEMENTAL TABLES
Supplemental Table S1. Fluorescent NI assay IC50 values for CDC Neuraminidase Inhibitor
Susceptibility Reference Virus Panel version 2.0a

Virus Name
A/California/12/2012 Wildtype
A/Texas/23/2012 H275Y
A/Washington/01/2007
Wildtype
A/Texas/12/2007
E119V
B/Rochester/02/2001 Wildtype
B/Rochester/02/2001 D198N
B/Memphis/20/96 Wildtype
B/Memphis/20/96 R152K

IC50 (nM)
Mean ± SD (Fold Change)b

Influenza
Type/Subtype
A(H1N1)pdm09
A(H1N1)pdm09
A(H3N2)
A(H3N2)
B
B
B
B

Oseltamivir

Zanamivir

0.20 ± 0.07 (1)
174.91 ± 18.58 (875)
0.08 ± 0.01 (1)
44.72 ± 7.15 (559)
7.34 ± 0.98 (1)
38.44 ± 4.48 (5)
4.25 ± 1.51 (1)
646.17 ± 90.32 (152)

0.13 ± 0.06 (1)
0.17 ± 0.02 (1)
0.96 ± 0.25 (1)
0.37 ± 0.02 (1)
0.74 ± 0.06 (1)
5.54 ± 0.83 (7)
1.01 ± 0.09 (1)
46.60 ± 8.39 (46)

Abbreviations - SD: Standard deviation
a

Source: CDC Neuraminidase Inhibitor Susceptibility Reference Virus Panel (version 2.0) - Product Information
Sheet and Instructions for Use.
b

Fold difference in IC50 determined by dividing the IC50 for the type/subtype-specific variant virus by that of the
corresponding wildtype matching virus.
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Supplemental Table S2. Median fluorescent NI assay IC50s of oseltamivir, zanamivir and peramivir obtained by the three NSRCIs (CDPH, USLPH and WSLH) and the CDC for U.S. influenza A and B surveillance isolates circulating during the 2011-15
influenza seasons
Median IC50 (nM), by influenza season
NAI

Oseltamivir

Zanamivir

Peramivir

Influenza Type/
Subtype

2011-12 (n=2767)a

2012-13 (n=2915)b

2013-14 (n=3681)c

2014-15 (n=3033)d

CDPH

USLPH

WSLH

CDC

CDPH

USLPH

WSLH

CDC

CDPH

USLPH

WSLH

CDC

CDPH

USLPH

WSLH

CDC

A(H1N1)pdm09

0.17

0.16

0.12

0.19

0.21

0.14

0.10

0.17

0.16

0.19

0.13

0.20

0.17

0.11

0.12

0.21

A(H3N2)

0.09

0.11

0.07

0.11

0.09

0.11

0.08

0.13

0.10

0.15

0.11

0.14

0.11

0.10

0.10

0.15

B

7.79

7.28

5.40

7.55

10.37

6.44

7.79

7.54

8.84

6.55

6.42

8.76

10.54

4.99

7.15

9.56

0.18

0.12

0.18

0.12

0.19

0.13

0.21

0.16

0.19

0.14

0.17

0.15

0.21

A(H1N1)pdm09

0.11

0.16

--e

A(H3N2)

0.15

0.23

--

0.25

0.17

0.26

0.17

0.26

0.18

0.30

0.22

0.20

0.15

0.23

0.20

0.20

B

0.76

1.08

--

1.19

1.02

1.00

0.69

1.05

0.58

0.89

0.77

0.73

0.98

0.80

0.58

0.84

A(H1N1)pdm09

0.05

0.06

0.03

0.05

--f

--

--

0.07

0.04

0.07

0.05

0.06

0.05

0.06

0.06

0.08

A(H3N2)

0.07

0.09

0.05

0.08

--

--

--

0.10

0.07

0.12

0.08

0.09

0.07

0.08

0.07

0.09

B

0.43

0.55

0.27

0.40

--

--

--

0.39

0.35

0.48

0.35

0.35

0.46

0.41

0.37

0.44

Abbreviations - CDPH: California Department of Public Health; USLPH: Utah Unified State Laboratories-Public Health; WSLH: Wisconsin State Laboratory of
Hygiene; CDC: Centers for Disease Control and Prevention.
a
Includes 940 U.S. virus isolates tested by NSRC-Is, and 1827 tested by CDC.
b
Includes 2114 U.S. virus isolates tested by NSRC-Is, and 801 tested by CDC.
c
Includes 2757 U.S. virus isolates tested by NSRC-Is, and 924 tested by CDC.
d
Includes 2460 U.S. virus isolates tested by NSRC-Is, and 573 tested by CDC.
e
Zanamivir was not available for testing in WSLH during 2011-12.
f
Peramivir was not assessed by NSRC-Is during 2012-13.
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